Multicentric prospective study for Therapy of Erectile Dysfunction After nerve sparing radical Prostatectomy: sildenafil (50 mg daily dosing) versus intracorporeal injection of alprostadil (2.5 µg - 10 µg 3/week)
- Conditions
- Urological and Genital DiseasesErectile dysfunction
- Registration Number
- ISRCTN32957197
- Lead Sponsor
- Johannes Gutenberg Universität Mainz (Germany)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Male
- Target Recruitment
- 194
1. Signed and dated informed consent indicating that the patient has been informed of all pertinent aspects of the trial before undergoing screening for the study
2. Ability of patient to understand character and individual consequences of clinical trial
3. Men older than 30 and younger than 65
4. Preoperative normal IIEF domain score more than 60 (total: 75)
5. Preoperative normal IIEF-EF domain score more than 25 (total: 30)
6. No neo-adjuvant therapy for prostate cancer before surgery
7. No use of drugs or devices for Erectile Dysfunction (ED) treatment before surgery (e.g. PDE-5-Inhibitor)
8. Patient in stable heterosexual relationship for at least six months
9. Planned surgery techniques: bilateral nerve sparing radical retropubic prostatatectomy
10. No adjuvant therapy after prostatectomy (i.e. androgen deprivation, radiatio therapy)
11. Documented clinical diagnosis of postoperative erectile dysfunction based on IIEF domain score less than 60
12. Documented clinical diagnosis of postoperative erectile dysfunction based on IIEF-EF domain score less than 25
1. Hypotension (Blood Pressure [BP] less than 90/50 mmHg)
2. Hypertension (BP more than 170/110 mmHg)
3. Patients with significant cardiovascular diseases in the last six months, including cardiac failure, myocardial infarction, unstable angina, stroke, symptomatic or clinically significant arrhythmias
4. Patients with blood coagulation disorder
5. Patients who are advised against sexual activity for medical reasons (e.g. patients with severe cardiovasucular disorders)
6. Patients who have conditions that might predispose them to priapism, such as sickle cell anaemia or trait, multiole myeloma, or leukaemia
7. Patients with severe liver insufficiency (e.g. cirrhosis, CHILD C)
8. Patients with severe kidney insufficiency (Creatinin-Clearance less than 30 ml/min)
9. Patients with hereditary degenerative retinal disorders such as Retinitis pigmentosa
10. Patients suffering from loss of vision on one eye due to Non-arteritic Anterior Ischemic Optic Neuropathy (NAION)
11. Patients with anatomical deformation of penis, such as angulation, cavernosal fibrosis or Peyronie´s disease
12. Known hypersensitivity to Sildenafil, Alprostadil or any compound of the trial medication
13. Patients with rare hereditary problems of galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption
14. Any of the investigational drugs taken four weeks prior to screening
15. Patients who are currently prescribed, taking and/or likely to be treated with nitrates or nitric oxide donors in any form on either a regular or intermittent basis
16. Patients being treated with alpha blockers for therapy of arterial hypertension
17. Patients who are receiving concomitant treatment with CYP3A4 inhibitor (e.g. ritonavir)
18. Alcohol or drug abuse
19. Participation in any other trial
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The primary outcome variable is the IIEF-EF domain score (six questions) measured at week 42, after 36 weeks of treatment and a therapy-free interval of six weeks.
- Secondary Outcome Measures
Name Time Method Secondary endpoints are:<br>1. IIEF-EF domain score (six questions) after week four, 12, 24, 36, and 52.<br>2. IIEF domain score (15 questions) after week four, 12, 24, 36, 42 and 52.<br>3. Erectile Dysfunction Inventory of Treatment Satisfaction (EDITS) after week four, 12, 24, 36, 42 and 52.<br>4. Patient satisfaction measured by patient diary during week five, week 13, 25, 37, 42 and 51.<br>5. Proportion of patients achieving a normal IIEF-EF domain score (more than 25) in week four, 12, 24, 36, 42 and 52.